Zosano Pharma Corporation is a biopharmaceutical enterprise, currently in the clinical development phase, focused on supplying therapeutic agents and other biologically active substances to patients afflicted with migraine using its specialized transdermal microneedle system. Their leading experimental compound, Qtrypta (M207), represents a distinct formulation of zolmitriptan, specifically intended for the swift management of acute migraine episodes. The company commenced operations in 2006 and maintains its principal offices in Fremont, California. Notably, Zosano Pharma Corporation initiated a voluntary Chapter 11 reorganization petition with the U.S. Bankruptcy Court for the District of Delaware on June 1, 2022.